Skip to main content
RT @ericdeinmd: 13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22
Novel Aspects
Macrovascular Domains - Venous and A

Eric Dein ericdeinmd

3 years 11 months ago
13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22 Novel Aspects Macrovascular Domains - Venous and Arterial by Low and High VTE, CVD risk profiles Microvasc - Suspected/Established @RheumNow https://t.co/M8NWRSyH4p
RT @DrPetryna: #abs1235 #acr22 @rheumnow
articular fibroblast activation in PSO assessed by 68Ga-FAPI-04 PET-CT assoctd

Olga Petryna DrPetryna

3 years 11 months ago
#abs1235 #acr22 @rheumnow articular fibroblast activation in PSO assessed by 68Ga-FAPI-04 PET-CT assoctd w/⬆️ risk of developing PsA. 10 pts assessed: 6/7 pts (85.7%)w/ 68Ga-FAPI-04 uptake at synovio-entheseal sites progressed to PsA. median PsA-free time 207 (160-240)days https://t.co/Y6EHPaDwfh
RT @uptoTate: PsA pts starting 1st DMARD tx, both early & late initiators experienced dz activity and PRO improvemen

Dr. Rachel Tate uptoTate

3 years 11 months ago
PsA pts starting 1st DMARD tx, both early & late initiators experienced dz activity and PRO improvements up to 6 months post-initiation. Better response, including MDA, achieved in pts initiating DMARD tx w/in 1 yr of dx. Abs 1493 #ACRbest #ACR22 @RheumNow https://t.co/a94sZRQ3VF https://t.co/OSUEoChtFf
RT @DrTrishHarkins: 🌟PSA vs RA 🌟
-UK cohort

PSA associated with:
👉⬆️ duration symptoms prior 2 referral
ð

Patricia Harkins DrTrishHarkins

3 years 11 months ago
🌟PSA vs RA 🌟 -UK cohort PSA associated with: 👉⬆️ duration symptoms prior 2 referral 👉⬆️ interval between GP presentation and DX 👉⬇️DMARD commencement 👉⬇️ improvement in Dx activity @ 3/12 # We need to do better #ACR22 Abst#1613 @RheumNow
RT @synovialjoints: Patients with PsA and AS who used opioids had higher healthcare utilization and higher costs. Also
â

Dr. Antoni Chan synovialjoints

3 years 11 months ago
Patients with PsA and AS who used opioids had higher healthcare utilization and higher costs. Also ➣ more comorbidities ➣ higher prevalence of smoking ➣ worse disease activity ➣ higher use of anti-rheumatic drugs Ogdie A Abs0402 https://t.co/3E4qAuqgpI #ACR22 @RheumNow https://t.co/AaKxiQXMwx
RT @RichardPAConway: Guan et al. Accuracy of financial disclosures in rheumatology journals. 76% papers >=1 inaccurac

Richard Conway RichardPAConway

3 years 11 months ago
Guan et al. Accuracy of financial disclosures in rheumatology journals. 76% papers >=1 inaccuracy. 78% authors >= undisclosed/underreported COI. Worse in clinical trials 85% @RheumNow #ACR22 Abstr#1267 https://t.co/dmqp3sj11f https://t.co/UXQgUCcGWb
RT @drdavidliew: What are we treating PMR with?

RISE registry, 2016-20 (n=26,102 in US)
- Such a small proportion ever

David Liew drdavidliew

3 years 11 months ago
What are we treating PMR with? RISE registry, 2016-20 (n=26,102 in US) - Such a small proportion ever see non-steroid therapies - Big chunk remain on steroids or lost to follow-up Surely we can improve PMR care! ABST1546 @SattuiSEMD @RADoctor #ACR22 @RheumNow https://t.co/Ocuw5WxKu2
RT @KDAO2011: Don't stop HCQ even after ESRD occurs in #LupusNephritis!
1578 pts w/ESRD on HCQ only, GCs only or HCQ+GC

TheDaoIndex KDAO2011

3 years 11 months ago
Don't stop HCQ even after ESRD occurs in #LupusNephritis! 1578 pts w/ESRD on HCQ only, GCs only or HCQ+GCs (n=509). HCQ groups had lower cardiac complications & infx compared to steroid only group. No diff. in thrombosis & all-cause mortality. #ACR22 @rheumnow #ACRbest abst#0539
RT @uptoTate: Higher NSAID intake is assoc'd w/ lower radiographic spinal progression, particularly in r-axSpA patients.

Dr. Rachel Tate uptoTate

3 years 11 months ago
Higher NSAID intake is assoc'd w/ lower radiographic spinal progression, particularly in r-axSpA patients. COX2i might have stronger inhibitory effect on radiographic progression compared to NS-NSAIDs. @ProftDr @RheumNow Abs 1492 #ACR22 https://t.co/l51wMqm5fB https://t.co/UaBCRRSJEE
RT @DrTrishHarkins: Subclinical GCA in PMR

🌟US findings of GCA in 22% PMR pts w/o signs or symptoms of GCA

🔥Diff

Patricia Harkins DrTrishHarkins

3 years 11 months ago
Subclinical GCA in PMR 🌟US findings of GCA in 22% PMR pts w/o signs or symptoms of GCA 🔥Different US pattern vs classical GCA Subclinical GCA: 👉predilection extra-cranial arteries 👉⬆️ IMT of large vessels #ACR22 @RheumNow Abst#1619 https://t.co/HV9dsTBfg8
RT @bella_mehta: Nurses’ Health Study - 34 yr f/u data #gout
- women with gout have ⬆️ risk of all-cause mortalit

Bella Mehta bella_mehta

3 years 11 months ago
Nurses’ Health Study - 34 yr f/u data #gout - women with gout have ⬆️ risk of all-cause mortality, - primarily driven by ⬆️ risk of CVD deaths. #ACR22 @rheumnow abst#1757 https://t.co/K2ykelHAlL
RT @ericdeinmd: 13S150. Draft ACR/EULAR APLS Classif Criteria
⭐️Reminder: Classification = high specificity, not Dia

Eric Dein ericdeinmd

3 years 11 months ago
13S150. Draft ACR/EULAR APLS Classif Criteria ⭐️Reminder: Classification = high specificity, not Diagnostic Crit! ⭐️Previously Sapporo: clinical (vasc/preg) + immunologic -- Lack of risk stratification, unclear definition of aPL+, no valvulopathy, outdated pregnancy @Rheumnow
RT @doctorRBC: Izokibep, a new IL-17Ai, demonstrated efficacy in treatment of psoriatic arthritis in a phase 2 study wit

Robert B Chao, MD doctorRBC

3 years 11 months ago
Izokibep, a new IL-17Ai, demonstrated efficacy in treatment of psoriatic arthritis in a phase 2 study with a safety profile similar to other IL-17i. Abs#1597 @RheumNow #ACR22 https://t.co/3LA9u8NsC4
RT @Yuz6Yusof: #ACR22 Abstr#0957 Do women with Anti-Ro/La+ get 1st screening for congenital heart block via foetal echo

Md Yuzaiful Md Yusof Yuz6Yusof

3 years 11 months ago
#ACR22 Abstr#0957 Do women with Anti-Ro/La+ get 1st screening for congenital heart block via foetal echo in time (16-18 wks)? A cohort study in 44 pregnancies found only 32% had =<18wks. 5 CHB detected (3 in 1st screening which was >19wks. This needs to improve @RheumNow https://t.co/dqJCCSwGLx
×